entera bio ltd. is a biotechnology company located in israel.
Company profile
Ticker
ENTX
Exchange
Website
CEO
Adam Gridley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Entera Bio Inc. ...
ENTX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
8 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
424B3
Prospectus supplement
15 Feb 24
EFFECT
Notice of effectiveness
15 Feb 24
S-3/A
Shelf registration (amended)
14 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
8-K
Regulation FD Disclosure
2 Feb 24
S-3
Shelf registration
2 Feb 24
Transcripts
ENTX
Earnings call transcript
2022 Q1
18 May 22
ENTX
Earnings call transcript
2021 Q4
8 Mar 22
ENTX
Earnings call transcript
2021 Q2
16 Aug 21
ENTX
Earnings call transcript
2021 Q1
20 May 21
ENTX
Earnings call transcript
2020 Q4
18 Mar 21
ENTX
Earnings call transcript
2020 Q3
19 Nov 20
ENTX
Earnings call transcript
2020 Q2
20 Aug 20
ENTX
Earnings call transcript
2020 Q1
21 May 20
ENTX
Earnings call transcript
2019 Q4
26 Mar 20
ENTX
Earnings call transcript
2019 Q3
21 Nov 19
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.68 mm | 7.68 mm | 7.68 mm | 7.68 mm | 7.68 mm | 7.68 mm |
Cash burn (monthly) | 508.33 k | 559.50 k | 795.33 k | 834.08 k | 508.33 k | 558.67 k |
Cash used (since last report) | 3.53 mm | 3.89 mm | 5.53 mm | 5.80 mm | 3.53 mm | 3.88 mm |
Cash remaining | 4.14 mm | 3.79 mm | 2.15 mm | 1.88 mm | 4.14 mm | 3.79 mm |
Runway (months of cash) | 8.2 | 6.8 | 2.7 | 2.3 | 8.2 | 6.8 |
Institutional ownership, Q2 2023
7.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 39.14 mm |
Total shares | 2.48 mm |
Total puts | 0.00 |
Total calls | 12.70 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Centillion Fund | 2.40 mm | $3.24 mm |
HRT Financial | 26.41 k | $22.00 k |
Geode Capital Management | 17.60 k | $14.96 mm |
Renaissance Technologies | 16.10 k | $14.00 k |
HighTower Advisors | 11.83 k | $10.00 mm |
PNC PNC Financial Services | 10.00 k | $8.43 mm |
MS Morgan Stanley | 1.10 k | $928.00 k |
UBS UBS Group AG - Registered Shares | 1.06 k | $897.00 k |
Advisor | 750.00 | $633.00 k |
RY Royal Bank Of Canada | 576.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Dana Yaacov-Garbeli | Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0 | 30,151 | 0.00 | 86,731 |
19 Apr 24 | Dana Yaacov-Garbeli | Stock Option Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 1.99 | 130,000 | 258.70 k | 130,000 |
19 Apr 24 | Hillel Galitzer | Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0 | 30,151 | 0.00 | 64,257 |
19 Apr 24 | Hillel Galitzer | Stock Option Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 1.99 | 130,000 | 258.70 k | 130,000 |
12 Jan 24 | Haya Taitel | Ordinary Shares, par value NIS 0.0000769 per share | Buy | Acquire P | No | No | 0.99 | 9,500 | 9.41 k | 35,115 |
10 Jan 24 | Haya Taitel | Ordinary Shares, par value NIS 0.0000769 per share | Buy | Acquire P | No | No | 0.77 | 7,615 | 5.86 k | 25,615 |
1 Jan 24 | Haya Taitel | Stock Option Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0.6 | 108,333 | 65.00 k | 108,333 |
News
Entera Bio Announces Publication Of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data I1n The Journal Of Bone And Mineral Research
8 Apr 24
HC Wainwright & Co. Maintains Buy on Entera Bio, Maintains $10 Price Target
2 Apr 24
Entera Bio Announces Key Regulatory Milestone For Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling On Qualifying BMD As A Surrogate Endpoint For Osteoporosis Drugs is Expected Within 10 Months
26 Mar 24
Entera Bio FY23 EPS $(0.31) Vs $(0.41) YoY; As Of December 31, 2023, Entera Had Cash And Cash Equivalents Of $11.0M
8 Mar 24
Entera Bio Regains Compliance With Nasdaq Minimum Bid Price Requirement
4 Mar 24
Press releases
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
8 Apr 24
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
26 Mar 24
Thinking about buying stock in Entera Bio, Ocugen, Mind Medicine, MicroAlgo, or Flora Growth?
25 Mar 24
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
8 Mar 24